What we are studying
The purpose of this study is to compare the effect on cancer of using either olaparib by itself or the combination of cediranib and olaparib to the usual chemotherapy given for cancer (carboplatin and paclitaxel; carboplatin and gemcitabine; or carboplatin and pegylated liposomal doxorubicin [PLD]). Any of these different approaches could shrink cancer but could also cause side effects. This study will allow the researchers to learn whether giving olaparib by itself or giving the combination of cediranib and olaparib is better, the same, or worse than the usual chemotherapy by observing both the effect of these treatments on cancer as well as any side effects that may be experienced.
Parking will be validated for study-related visits.